Business
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md.,
About this update from Altimmune, Inc.
[{"type":"text","content":"Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that 24-week data from its Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented in late-breaking oral and poster presentations at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 7–11, 2025. Details of the presentations are as follows: Poster Presentation Details Abstract Title: Reduction of Liver Fibrosis by AI-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2 IMPACT TrialSession: Saturday Late-Breaking Posters (publication number 5025)Date/Time: The presenter will present/take questions during Poster Session II on Saturday, November 8, 2025 from 1:00 – 2:00 p.m. ET. The poster will be on display throughout The Liver Meeting®Presenter: Dr. Julio Gutierrez, Transplant Hepatologist at the Scripps Organ and Cell Transplant Program and Senior Medical Director at Altimmune Oral Presentation Details Abstract Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated SteatohepatitisSession: Late-Breaking Abstracts Parallel Session 3 (publication number 5001)Date/Time: Tuesday, November 11, 2025 at 11:45 a.m. ETPresenter: Dr. Mazen Noureddin, Professor of Medicine at the Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research The AASLD late-breaking presentations will focus on the recent IMPACT Phase 2b readout of the 24-week data. In addition, Altimmune expects to announce 48-week data in Q4 2025. A copy of the presentation and poster will be accessible on the Events section of the Altimmune website. About the Phase 2b IMPACT Study The IMPACT (NCT05989711) trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg, or placebo for 24 weeks. Key efficacy endpoints were MAS...